<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
PNT
Point Biopharma
$
()


  • One new option listing and sixteen option delistings on January 23rd

    1/23/2024 - 08:30am
  • Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls

    12/27/2023 - 11:02am
  • Eli Lilly completes the acquisition of Point Biopharma

    12/27/2023 - 08:56am
  • Recent M&A activity bodes well for Fusion Pharmaceuticals, says Oppenheimer

    12/27/2023 - 08:27am
  • Fusion Pharmaceuticals upgraded at Raymond James amid radiopharma M&A

    12/27/2023 - 08:21am
  • Cantor says Bristol joins 'radiopharmaceuticals race' with RayzeBio deal

    12/27/2023 - 07:11am
  • Pnt Biopharma Global put volume heavy and directionally bearish

    12/22/2023 - 11:55am
  • Salesforce upgraded, Chipotle downgraded: Wall Street's top analyst calls

    12/21/2023 - 10:02am
  • Point Biopharma just downgraded at Brookline, here's why

    12/21/2023 - 05:34am
  • Largest borrow rate increases among liquid names

    12/20/2023 - 08:45am
  • Purple Biotech appoints Margolin to board, announces resignation of CBO

    12/20/2023 - 08:22am
  • Unusually active option classes on open December 19th

    12/19/2023 - 09:40am
  • Lantheus, Point Biopharma report SPLASH trial met primary endpoint

    12/18/2023 - 07:49am
  • Lantheus, Point Biopharma report topline results from Phase 3 SPLASH trial

    12/18/2023 - 07:47am
  • Eli Lilly extends expiration of tender offer to acquire Point Biopharma

    12/18/2023 - 06:59am
dynamic_feed Breaking News